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Socrates was a classical Greek scholar who had a reputation for teaching by asking questions 
but not necessarily providing answers. Naming a randomized trial after him is tempting fate. 
You might just get what you ask for – questions but no clear answers! 
 
The SOCRATES (SOluble guanylate Cyclase stimulatoR in heArT failurE Studies) 
programme set out to identify one or more preferred doses of vericiguat, to take forward into 
major outcome trials for the treatment of recently re-compensated heart failure1. There were 
two component trials; one for left ventricular ejection fraction (LVEF) <45% (SOCRATES-
REDUCED2) and the other for LVEF >45% (SOCRATES –PRESERVED3). The primary 
end-point for both was the change in amino-terminal pro-B-type natriuretic peptide (NT-
proBNP); left atrial volume index was a co-primary end-point in SOCRATES-PRESERVED. 
Neither study met its primary endpoint. In SOCRATES-REDUCED, titration to the highest 
dose of vericiguat, 10mg/day, was associated with a fall in NT-proBNP, an increase in 
hypotensive episodes (although no difference in average blood pressure), a modest increase 
in LVEF and numerically fewer hospitalisations for worsening heart failure. In SOCRATES-
PRESERVED, no effect on NT-proBNP or left atrial volume index was observed at any dose, 
there was no increase in hypotensive episodes, no obvious effect on worsening heart failure 
but a numerical increase in deaths with vericiguat. In one of many exploratory analyses, an 
improvement in quality of life was identified, largely driven by improved symptoms, amongst 
those titrated to the 10mg dose of vericiguat. SOCRATES-PRESERVED was marred by 
some errors in randomization.  
 
Is this the correct way to phenotype heart failure? These studies used a combination of a 
clinical diagnosis, evidence of congestion requiring administration of diuretics, LVEF, an 
elevated plasma NT-proBNP and, if LVEF was >45%, left atrial dilatation to select patients 
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and stratify them into component trials. These are robust diagnostic criteria for heart failure 
but do not conform to the three LVEF phenotypes proposed by recent ESC guidelines4: 
reduced (HFrEF), mid-range (HFmrEF) and preserved (HFpEF). In clinical practice, LVEF 
measured by echocardiography has considerable observer variability. This was a key driver 
for the introduction of HFmrEF. Using a single threshold value (ie:- 40%) to distinguish 
HFrEF from HFpEF will misclassify many patients because of measurement error. Having 
HFmrEF as a grey-zone ensures that, in the future, few HFrEF patients will be misclassified 
as HFpEF and vice versa and that if a treatment is shown to be effective then it is clear for 
which phenotypes. HFmrEF may be uncommon as the first attempted clinical trial failed to 
enrol patients and was abandoned5. Pragmatically, if a treatment is shown to be effective for 
both HFrEF and HFpEF then it might be assumed to be effective for HFmrEF. On the other 
hand, a study that included both HFmrEF and HFpEF would need to show that the treatment 
was effective in the subgroup with HFpEF before clinicians could be sure that it was not just 
effective for patients with milder degrees of left ventricular systolic dysfunction, as in a 
recent study of spironolactone6.  Of course, this all pre-supposes that LVEF is a useful way to 
phenotype heart failure. LVEF might just be a surrogate marker for other characteristics that 
are important determinants of outcome or treatment effect, including age, sex, the aetiology 
of ventricular dysfunction, the prevalence of atrial fibrillation and other co-morbidities or 
NT-proBNP. We should not forget that the idea of using LVEF as an entry criterion for 
studies of heart failure is less than 30 years old7.  
 
Is NT-proBNP a useful surrogate end-point for Phase II studies in heart failure? NT-proBNP 
is the most powerful, simple, widely available prognostic marker in patients with chronic 
heart failure8. However, plasma concentrations of natriuretic peptides in patients with known 
heart failure are not strong predictors of an adverse prognosis when measured during the 
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acute phase (eg:- the first 24h) of decompensated heart failure9,10. This may reflect a strength 
rather than a weakness. If a biomarker measured during the acute phase predicts longer-term 
prognosis then either it is a poor measure of decompensation or it is unresponsive to change 
and of little use in monitoring. If NT-proBNP is measured serially, then the last measured 
value carries most of prognostic information11,12. Treatments that improve prognosis, 
including angiotensin converting-enzyme inhibitors, mineralo-corticoid antagonists, 
angiotensin-receptor neprilysin inhibitors, cardiac resynchronization therapy and, more 
controversially, beta-blockers13, all reduce NT-proBNP and improve prognosis. Diuretics are 
possibly the most effective agents for reducing NT-proBNP 14 and there is little doubt that 
diuretics are life-saving in severely congested patients. If NT-proBNP is a marker of 
congestion, a pathophysiology driven by both cardiac and renal dysfunction, and congestion 
is a marker of prognosis, this provides a rationale for, and limitation of, using it as a surrogate 
end-point in clinical trials. In decompensated heart failure, an acute intervention might 
temporarily relieve congestion and transiently reduce NT-proBNP. However, if the effect 
does not persist then an improvement in longer-term prognosis should not be expected. On 
the other hand, an intervention that causes a persistent reduction in NT-proBNP, should lead 
to improved prognosis. Whether this hypothesis is true requires the test of time and many 
more prospective confirmatory trials. Whether other biomarkers, such as troponin, can 
provide supplementary information also requires investigation. 
 
Clearly, the published studies of vericiguat do not provide a strong argument for progressing 
to large outcome trials. On the other hand, they do offer some evidence of an effect. How 
then to proceed? The first issue is to focus on the ultimate treatment goals, which should 
either be important to the patient or clinician or society and preferably all three. These might 
include improvement (or prevention of worsening) in symptoms and well-being, reductions in 
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disability and morbidity, maintenance of independence or prolongation of life. Alternatively, 
an intervention that simplifies management and/or reduces costs might be worthwhile. The 
treatment goals will determine the target population and the size and duration of the next 
study. As most patients with heart failure are already receiving many medications, the 
treatment should either have a substantial benefit in order to convince physicians and patients 
to take an additional therapy or it needs to simplify management, for instance by making 
other treatments redundant. The most important therapeutic outcome will vary according to 
context and individual patient. For a patient with severe unremitting symptoms the most 
important outcome may not be survival but symptom relief. Paradoxically, it is probably the 
patient with heart failure who has the fewer symptoms and a better prognosis for whom 
longevity is the most important target. Large trials are required to demonstrate safety but 
unless a treatment is effective, safety is a clinically irrelevant since only effective treatments 
should be used. 
 
If a treatment has a useful and consistent effect on symptoms and functional capacity then 
some form of cross-over trial should be considered, since using the patient as their own 
control greatly increases statsitical power. Such a trial should require less than one hundred 
patients. If it requires more, then the effect is unlikely to be of great clinical utility. Of course, 
enrolling the right patient is critical; you can only fix a problem if it exists. Although 
symptoms are often what provoke the patient to seek medical help, neither guidelines nor 
recent clinical trials pay great attention to improving them. Indeed, pride of place for 
improving symptoms is given to diuretics. This raises the question of what the comparator 
should be for trials investigating the effects of treatments on symptoms; should it be placebo, 
an increased dose of diuretic or both? This will increase the complexity of the study design 
but, for an effective agent, would ensure clinical relevance. Several agents have improved 
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symptoms of HFpEF in clinical trials and yet these have not caused guidelines to recommend 
their use15. It is important that guidelines on heart failure are not just about procrastinating 
death but rather provide recommendations to promote the broader well-being of patients. 
There is a view that for heart failure health services, unlike for many other diseases, are less 
welling to pay for treatments that only improve symptoms but not prognosis.  
 
Industry is required to charge a premium price for new treatments because they have to get a 
return on investment within a relatively short space of time. On solution is longer patent 
protection on new treatments, akin to that for artists who get at least 70 years from first 
performance16. Long patents would allow companies to get a return on their investment 
through volume and duration of sales rather than high costs. Health systems might pay 
roughly the same amount but over a longer period of time. If the focus remains on reducing 
morbidity and mortality, then large studies will be required. Most clinical trials that have 
revolutionised care enrolled fewer than 3,000 patients and most were stopped early because 
of the size of benefit (Figure 1). With the increasing cost and complexity of delivering care, 
the practical clinical value of demonstrating small benefits becomes questionable and 
potentially unaffordable. Recently, the PARADIGM-HF study demonstrated the superiority 
of sacubitril-valsartan over enalapril in more than 8,000 patients but sacubitril-valsartan only 
received a class 1B recommendation in guidelines; to gain a Class 1A recommendation 
requires a confirmatory trial in a similar population, which seems unlikely to happen.  
 
We think Socrates would have been flattered to know that his memory had been honoured by 
having a clinical trial named after him more than 2,000 years after his death. To quote Earl C. 
Kelley 17“We have not succeeded in answering all our problems. The answers we have found 
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only serve to raise a whole set of new questions. In some ways we feel we are as confused as 
ever, but we believe we are confused on a higher level and about more important things.”  
 
  
Page 8 of 12 
 
Legend to Figure 
Trial size compared to percentage reduction in all-cause mortality in landmark clinical trials 
of heart failure with a reduced left ventricular ejection fraction. Major trials of agents 
available in one or more country belonging to the European Society of Cardiology are shown. 
CONSENSUS:  Cooperative North Scandinavian Enalapril Survival Study. 
SOLVD: Studies Of Left Ventricular Dysfunction 
CHARM-Reduced:- candesartan in heart failure: assessment of reduction in mortality and 
morbidity 
ATMOSPHERE*:- Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure 
(note that the effect on all-cause mortality was inconclusive, since the point estimate did not 
reach statistical significance) 
CIBIS-II: Cardiac Insufficiency Bisoprolol Study-II 
MERIT-HF:- Metoprolol CR/XL (Controlled Release/Extended Release) Randomized 
Intervention Trial in Chronic Heart Failure 
COPERNICUS:- Carvedilol Prospective Randomized Cumulative Survival study 
RALES:- Randomized Aldactone Evaluation Study 
EMPHASIS:- Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart 
Failure 
COMPANION#:- Comparison of Medical Therapy, Pacing, and Defibrillation in Heart 
Failure (cardiac resynchronization therapy with defibrillator versus control arms only)  
CARE-HF:- Cardiac Resynchronization — Heart Failure Study 
MADIT-II:- Multicenter Automatic Defibrillator Implantation Trial-II 
SCD-HeFT:- Sudden Cardiac Death in Heart Failure Trial 
RAFT:- Resynchronization-Defibrillation for Ambulatory Heart - Therapy Failure Trial 
(RAFT) 
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PARADIGM-HF:- Prospective Comparison of ARNI [Angiotensin Receptor–Neprilysin 
Inhibitor] with ACEI [Angiotensin-Converting–Enzyme Inhibitor] to Determine Impact on 
Global Mortality and Morbidity in Heart Failure Trial. Data are also shown for sacubitril –
valsartan versus an imputed placebo)  
SHIFT*:- Systolic Heart failure treatment with the If inhibitor ivabradine Trial (note that the 
effect on all-cause mortality was inconclusive, since the point estimate did not reach 
statistical significance) 
 
RELAX-AHF:- RELAXin in Acute Heart Failure (note that all-cause mortality was not a pre-
specified primary or secondary endpoint in this study) 
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